Making Biliary Tract Cancer Treatment More Precise
Researchers are examining ways to make treatments more targeted to each type of biliary tract cancer or to each patient.
Progress Against Cancer
Researchers are examining ways to make treatments more targeted to each type of biliary tract cancer or to each patient.
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris), in...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for the treatment of patients with neurofibromatosis...
Researchers explore musical toxicity from cancer treatment, and kidney cancer vaccine shows potential in early trial.
FDA approves an antibody-drug conjugate for people with HER2-ultralow breast cancer, and historic redlining practices have a lingering impact on cancer outcomes.
As winter marches on, let’s dive into the cool articles highlighted this month by the editors of the AACR journals. Grab a blanket and keep reading to learn how nicotine levels in e-cigarettes impact...
The FDA has approved fam-trastuzumab deruxtecan-nxki for certain HER2-low or HER2-ultralow breast cancers. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of unresectable or metastatic, hormone...
Studies underscore the strength of exercise recommendations, and new radiation therapy technique poised to make a flash.
A therapeutic HPV vaccine showed remarkable benefits for patients with high-grade cervical precancers.
The FDA approved treosulfan and fludarabin for patients with hematologic disorders prior to stem cell transplantation. The U.S. Food and Drug Administration (FDA) has approved treosulfan (Grafapex) with fludarabine for people with acute...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More